On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases.
Crohn’s disease
IL-6
adalimumab
cytokines
sCD163
ulcerative colitis
ustekinumab
vedolizumab
zonulin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Mar 2020
15 Mar 2020
Historique:
received:
24
02
2020
revised:
12
03
2020
accepted:
13
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (
Identifiants
pubmed: 32183476
pii: jcm9030800
doi: 10.3390/jcm9030800
pmc: PMC7141255
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
World J Gastroenterol. 2014 Jan 7;20(1):6-21
pubmed: 24415853
Scand J Immunol. 2014 Dec;80(6):417-23
pubmed: 25346048
Scand J Gastroenterol. 2018 Apr;53(4):379-389
pubmed: 29523023
Minerva Gastroenterol Dietol. 2019 Dec;65(4):298-308
pubmed: 31646851
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Minerva Med. 2017 Jun;108(3):239-254
pubmed: 28176515
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
BMC Gastroenterol. 2018 Nov 6;18(1):167
pubmed: 30400824
Am J Gastroenterol. 2011 Apr;106(4):685-98
pubmed: 21427713
J Clin Med. 2019 Nov 14;8(11):
pubmed: 31739460
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
United European Gastroenterol J. 2019 Jun;7(5):709-715
pubmed: 31210949
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
Pathogens. 2019 Aug 13;8(3):
pubmed: 31412603
J Clin Invest. 2008 Jun;118(6):2269-80
pubmed: 18497880
PLoS One. 2013 Jul 26;8(7):e69839
pubmed: 23922818
Inflamm Bowel Dis. 2019 Nov 14;25(12):1896-1905
pubmed: 30934053
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Inflamm Bowel Dis. 2015 Sep;21(9):2114-22
pubmed: 26218144
Gut. 2009 Jan;58(1):41-8
pubmed: 18829978
F1000Res. 2020 Jan 31;9:
pubmed: 32051759
Immune Netw. 2017 Feb;17(1):25-40
pubmed: 28261018
Br J Clin Pharmacol. 2020 Feb 6;:
pubmed: 32027388
Lancet. 1980 May 24;1(8178):1134-5
pubmed: 6103463
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Inflamm Intest Dis. 2019 Aug;4(3):79-96
pubmed: 31559260
Scand J Gastroenterol. 2018 May;53(5):579-585
pubmed: 29171305
Expert Opin Biol Ther. 2019 Nov;19(11):1207-1217
pubmed: 31373244
Physiol Rev. 2011 Jan;91(1):151-75
pubmed: 21248165
J Clin Med. 2019 Dec 30;9(1):
pubmed: 31905945
J Crohns Colitis. 2013 Dec;7(11):916-22
pubmed: 23339932
Am J Transl Res. 2016 Jun 15;8(6):2490-7
pubmed: 27398134
Minerva Med. 2019 Apr;110(2):95-100
pubmed: 30160088